Business Context and Reporting Period
This Form 8-K is a current report filed by Pharmathene, Inc. (not Altimmune, Inc.) on September 3, 2015, covering events occurring on September 1, 2015. The filing addresses a significant change in executive leadership.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is limited to corporate governance updates and contains no financial performance data.
Material Changes
- Executive Departure: Jeffrey Jones, Vice President and Chief Operating Officer, resigned effective September 17, 2015.
- Notice Date: Resignation notice was delivered on September 1, 2015.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, or discussion of risks and contingencies beyond the immediate impact of the officer's departure. No unusual items were reported.
Investor Verification Checklist
- Confirm the appointment of a successor to the Chief Operating Officer role.
- Review subsequent filings for any transition plans or strategic shifts resulting from the resignation.
- Verify the company name discrepancy in the request metadata (filing is for Pharmathene, Inc., not Altimmune, Inc.).